
Insilico Medicine and CMS announce CNS disease collaboration
Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), and China Medical System Holdings has announced an AI‑empowered drug discovery collaboration. The collaboration is targeting a mass-market indication in central nervous system (CNS) with an innovative mechanism of action (MoA) identified by PandaOmics. According to the collaboration agreement, the two parties will jointly advance the co-development… Read More













